Nectar Lifesciences Ltd.

Ref: NLL\CS\2024- 428 **November 14, 2024**

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations")

Dear Sirs/ madams,

Pursuant to captioned regulations, please be informed that Mr. Vikas Vij has been appointed as Chief Operating Officer ("COO") of the Company w.e.f. November 14, 2024.

The details as required under LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in Annexure A.

The Stock Exchanges may kindly take the same in record.

Yours faithfully,
For **Nectar Lifesciences Limited**

Neha Vaishnav
Digitally signed by Neha Vaishnav
Date: 2024.11.14 14:34:47 +05'30'

(Neha Vaishnav)
Company Secretary & Compliance Officer

Annexure – A

Details as required as per LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are as follows:

Sr. No.	Particulars	Details
1.	Reason for change viz. Appointment~~, re-appointment, resignation, removal, death~~ or otherwise	Appointment of Mr. Vikas Vij as Chief Operating Officer ("COO")
2.	Date of appointment~~/re-appointment~~/ cessation (as applicable) & term of appointment/re-appointment	November 14, 2024.
3.	Brief profile (in case of appointment)	Mr. Vikas Vij, aged 57 years, is a Chemical Engineer with Post Graduation from Indian Institute of Foreign Trade (IIFT), New Delhi. He is a leading Pharma Professional with over three decades of experience spanning from start-ups to established corporations, driving global strategies and operational excellence in APIs, CDMO, Formulations and Chemicals sectors. He has worked with leading Companies such as Cipla, Sun Pharma, Ranbaxy and Aragen. His last assignment had been as Chief Executive Officer in IOL Chemicals and Pharmaceuticals Limited. His expertise lies in crafting comprehensive strategic roadmaps, setting and achieving ambitious growth objectives, expanding customer bases, forging key executive-level relationships, conceptualizing innovative products to meet evolving market demands and navigating diverse markets across continents. He has consistently delivered exceptional results. His focus areas include prioritizing operational efficiency, implementing measures to enhance productivity, streamline processes, and

		ensure top-notch product quality and regulatory compliance.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable
5.	Certification of Director as per BSE Circular no. LIST/COMP/14/2018-19 and the NSE Circular no. NSE/ CML/2018/24, both dated 20 June 2018	Not applicable
6.	Shareholding in the Company	Nil
7.	Certification of Criteria of Independence in case of Independent Director	Not applicable